Proteomics Analyses for the Global Proteins in the Brain Tissues of Different Human Prion Diseases

Qi Shi†, Li-Na Chen‡, Bao-Yun Zhang‡, Kang Xiao‡, Wei Zhou‡, Cao Chen‡, Xiao-Mei Zhang‡, Chan Tian‡, Chen Gao‡, Jing Wang‡, Jun Han‡, and Xiao-Ping Dong‡¶

Proteomics changes of brain tissues have been described in different neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. However, the brain proteomics of human prion disease remains less understood. In the study, the proteomics patterns of cortex and cerebellum of brain tissues of sporadic Creutzfeldt-Jakob disease, fatal familial insomnia, and G114V genetic CJD were analyzed with isobaric tags for relative and absolute quantitation combined with multidimensional liquid chromatography and MS analysis, with the brains from three normal individuals as controls. Global protein profiling, significant pathway, and functional categories were analyzed. In total, 2287 proteins were identified with quantitative information both in cortex and cerebellum regions. Cerebellum tissues appeared to contain more up- and down-regulated proteins (727 proteins) than cortex regions (312 proteins) of Creutzfeldt-Jakob disease, fatal familial insomnia, and G114V genetic CJD. Viral myocarditis, Parkinson’s disease, Alzheimer’s disease, lysosome, oxidative phosphorylation, protein export, and drug metabolism-cytochrome P450 were the most commonly affected pathways of the three kinds of diseases. Almost coincident biological functions were identified in the brain tissues of the three diseases. In all, data here demonstrate that the brain tissues of Creutzfeldt-Jakob disease, fatal familial insomnia, and G114V genetic CJD have obvious proteomics changes at their terminal stages, which show the similarities not only among human prion diseases but also with other neurodegeneration diseases. This is the first study to provide a reference proteome map for human prion diseases and will be helpful for future studies focused on potential biomarkers for the diagnosis and therapy of human prion diseases.  

Molecular & Cellular Proteomics 14: 10.1074/mcp.M114.038018, 854–869, 2015.

Human prion diseases, also named human transmissible spongiform encephalopathies (TSEs)1, are fatal neurodegenerative disorders, including Kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker disease (GSS), and fatal familial insomnia (FFI). These various subtypes of human TSEs differed with each other in the aspects of clinical symptoms, neuropathology, and genetics, but all eventually undergo fatal consequence (1). The conversion of prion protein (PrP), coded by the PRNP gene, from its cellular isoform PrP(C) to its pathogenic isoform PrPSc through a post-translational process is considered the etiology of these diseases (2). Human TSEs can be also etiologically classified as sporadic, such as sporadic CJD (sCJD), genetic or familial, such as genetic CJD (gCJD), GSS, and FFI, and acquired, such as iatrogenic CJD (iCJD) and variant CJD (vCJD). During the long-term pathogenesis of human TSEs, besides of accumulating…

1 The abbreviations used are: TSEs, transmissible spongiform encephalopathies; AD, Alzheimer’s disease; PD, Parkinson’s disease; sCJD, sporadic Creutzfeldt–Jakob disease; FFI, fatal familial insomnia; gCJD, G114V genetic CJD; iCJD, iatrogenic CJD; vCJD, variant CJD; GSS, Gerstmann–Sträussler–Scheinker disease; iTRAQ, Isobaric tags for relative and absolute quantitation; LC, liquid chromatography; PrP, prion protein; GO, Gene Ontology; PSE, periodic sharp-waves; EEG, electroencephalogram; MRI, Magnetic resonance imaging; CSF, Cerebrospinal fluid; BCA, bicinchoninic acid; TEAB, tetraethylammonium bicarbonate; SCX, strong cation exchange; HPLC, high performance liquid chromatography; MALDI-TOF/TOF, matrix-assisted laser desorption/ionization time-of-flight/time-of-flight; HCD, higher collision energy dissociation; CID, collision induce dissociation; NCE, normalized collision energy; KEGG, Kyoto Encyclopedia of Genes and Genomes; ALS, Amyotrophic lateral sclerosis; TGN, trans-Golgi network.
lation of PrP<sup>Sc</sup> in brain tissues, numerous brain proteins, which are involved in many different biological processes and pathways, have been described to be abnormally changed (3, 4, 5). Recently, the global transcriptional profiles in the brain tissues of some kinds of human TSEs, for example, sCJD, gCJD, and FFI have been reported with the help of high throughput microarray technique (6, 7). However, the global changes of proteins in the brain tissues, which are definitely important for understanding the pathogenesis of the disease and providing the clues for the disease diagnosis and therapy, remains seldom addressed.

The rapid development of proteomics technologies in the past decade allows scientists to be able to define the global protein expression profiles in specific physical or pathological statuses, which are usually not fulfilled by conventional molecular biological technologies (8). Isobaric tags for relative and absolute quantitation (iTRAQ) combined with multidimensional liquid chromatography (LC) and MS analysis is a widely accepted quantitative proteomics that allows a single MS analysis with multiple samples, leading to significant reduction of experimental errors generated from individual experiments (9). The approach allows for sample multiplexing, which can be up to eight-plex at the same time. iTRAQ is particularly powerful when applied on a subtraction of the proteome, thereby increasing the possibility of identifying less abundant proteins (10). All these advantages allow the method to reduce chemical noise and improve quantification accuracy, in addition to improving statistical analysis and augmenting data confidence.

To investigate the global protein alterations in the brain tissues of human TSEs, the postmortem cortex and cerebellum tissues from Chinese patients with sCJD, FFI, and G114V gCJD were profiled with iTRAQ analysis, using normal Chinese brain tissues as control. Total 2287 proteins were identified in all of the tested brain samples. In the context of three human TSEs, 161 and 151 proteins were commonly up-regulated and down-regulated in the cortex region, whereas 348 and 379 proteins were commonly up-regulated and down-regulated in the cerebellum region, respectively. FFI had less protein expression changes of proteins in the brain tissues, which are definitely important for understanding the pathogenesis of the disease and providing the clues for the disease diagnosis and therapy, remains seldom addressed.

EXPERIMENTAL PROCEDURES

Ethics Statement—Usage of the stored human brain samples in the China CJD Surveillance System has been approved by the Research Ethics Committee of National Institute for Viral Disease Control and Prevention, China CDC.

Patients—Human cortex and cerebellum samples collected from the patients with definitely diagnosed sCJD, FFI, or G114V gCJD were enrolled in this study. Meanwhile, the brain tissues from three Chinese individuals that died from accidents were used as normal controls including a 50 year-old man, a 63 year-old man, and a 42-year-old woman. All of them did not have a history of neurological symptoms and chronic disease. The sCJD patient was an 80-year-old man with progressive disturbance of consciousness. One month later, he developed obvious akinetic mutism and inactivity, and subsequently many other symptoms appeared such as alalia, apathy, drowsiness, and pyramidal symptoms. Typical periodic sharp-waves (PSW) were detected in electroencephalogram (EEG). Magnetic resonance imaging (MRI) did not reveal a specific abnormality. Cerebrospinal fluid (CSF) 14–3-3 protein was not performed. The patient died 13 months after onset. Neuropathological assays revealed extensive spongiform degeneration and PrP<sup>Sc</sup> deposits. Western blot identified type I PrP<sup>Sc</sup> in brain tissues. PRNP sequencing analysis did not find any nucleotide exchange. Polymorphism of codon 129 was Met/Met homology. The clinical, genetic, neuropathological, and PrP<sup>Sc</sup> molecular features of three cases of FFI (11, 12) and one case of G114V gCJD were described in detail in our previous work (13). The main clinical features of the enrolled cases were summarized in Table I.

Protein Extraction and Protein Digestion—Brain region samples of parietal lobe and cerebellum were homogenized 1:10 in PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na<sub>2</sub>HPO<sub>4</sub>, 2 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.4) according to the protocol described elsewhere (14). Tissue debris was removed with low speed centrifugation at 2000 × g for 10 min and the supernatants were collected. The protein concentration was determined by bicinchoninic acid (BCA) method and the samples were stored at −80 °C for further study. SDS-PAGE was performed to verify the protein quality and concentration.

One hundred micrograms of each protein sample was combined with different volumes of tetraethylammonium bicarbonate (TEAB) with 0.1% SDS to equal volume level followed by treatment with trypsin (3.3 μg trypsin/100 μg total protein). The proteins in TEAB were digested with trypsin at 37 °C for 24 h and then another 1 μg trypsin was added in the proteins and digested at 37 °C for another 12 h. The solvent was removed using a SpeedVac.

iTRAQ Labeling—The iTRAQ labeling procedure was performed following the manual provided in the iTRAQ labeling kit (Applied Biosystems, Foster City, CA). The digested samples were dissolved in 30 μl of 50% TEAB together with 70 μl of isoprotocol and labeled with the iTRAQ reagents according to the protocol of the eight-plex iTRAQ labeling kit, including iTRAQ 113–119 and 121. The iTRAQ-labeled products were then pooled and subjected to strong cation exchange (SCX) fractionation.

Peptide Fractionation by the HPLC Approach and Peptide Identification by Nano RP HPLC and Mass Spectrometry—The processes of protein fractionation by HPLC and protein identification by nano RP HPLC and mass spectrometry were performed at Beijing Institute of Genomics, Chinese Academy of Science, based on a fixed methodology published previously (15). To separate the peptides, two different HPLC approaches were adopted, high-pH RP and strong cation exchange (SCX). In the high-pH RP HPLC procedure, the peptides were loaded onto a RP column (Luna C18, 4.6 mm inner diameter × 250 mm length, Phenomenex, Los Angeles, CA), and eluted by step linear elution program, 0–10 min equilibrated in 100% solution A (2% ACN and 20 mM NH<sub>4</sub>FA, pH 10), 10–15 min fast elution from 0–12% of solution B (80% ACN and 20 mM NH<sub>4</sub>FA, pH 10), 15–50 min linear elution from 12–56% of solution B; and 50–55 min washing elution from 56–80% of solution B. In the SCX HPLC procedure, the peptides were loaded onto a SCX column (Luna SCX, 4.6 mm × 250 mm, Phenomenex), and eluted by step linear elution program, 0–10 min equilibrated in buffer A (25% ACN, 20 mM KCl, and 10 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.4) to 10–20 min
Proteomics Analyses of Human Prion Disease

Comparison of the main clinical features of the five human TSE patients

| Age of onset (y) | Gender | Case No. | Other signs and symptoms | Foremost symptoms | Blood pressure (mmHg) | Other symptoms | EEG | MRI | Time of illness (m) | Question of illness | Duration of illness (m) | Other signs and symptoms | Duration of illness (m) | Time of diagnosis after onset (m) |
|-----------------|--------|----------|--------------------------|------------------|---------------------|---------------------|-----|-----|-------------------|---------------------|---------------------|--------------------------|---------------------|------------------------|
| 80              | M      | sCJD     | Insomnia, dysautonomia,  | Pyramidal system  | 145/95              | No                  | Yes | Yes | 1                 | -                   | 10                  | -                        | -                   | -                      |
| 45              | M      | FFI1     | Progressive dementia,    | Sleep disturbance | 142/96              | Yes                 | Yes | Yes | 2                 | ND                  | 10                  | -                        | -                   | -                      |
| 26              | F      | FFI2     | Emotional lability       | Sleep disturbance | 142/96              | Yes                 | No  | Yes | 1                 | ND                  | 14                  | -                        | -                   | -                      |
| 55              | M      | FFI3     | Sleep disturbance,       | Progressive dementia, | 145/95              | Yes                 | Yes | Yes | 2                 | ND                  | 2                   | -                        | -                   | -                      |
| 47              | F      | G114V    | Sleep disturbance,       | Progressive dementia, | 145/95              | Yes                 | Yes | Yes | 2                 | ND                  | 8                   | -                        | -                   | -                      |

The proteins whose impurities and normalization of intensity median were used as analysis methods for protein ratio type, correction of isotope labeled with iTRAQ. Second, false discovery rate (FDR) was performed. The eluted fractions were delivered onto a nano RP column (5-μm Hypersil C18, 75 μm × 150 mm, Thermo Fisher Scientific, Waltham, MA) and were eluted with acetonitrile (ACN) gradient from 5–40% containing 0.1% formic acid, for 95 min at 400 nl/min. The elution products were directly entered Q-Exactive MS (Thermo Fisher Scientific), setting in positive ion mode and data-dependent manner with full MS scan from 350–2000 m/z, full scan resolution at 70,000, MS/MS scan resolution at 17,500. MS/MS scan with minimum signal threshold 1E+5, isolation width at 2 Da. To evaluate the performance of this mass spectrometry on the iTRAQ labeled samples, higher collision energy dissociation (HCD) for MS/MS acquisition modes was employed. To optimize the MS/MS acquisition efficiency of HCD, normalized collision energy (NCE) was systematically examined 28% and stepped 20%.

Database Searches for Peptide and Protein Identification—The raw MS/MS data were converted into MGF format by Thermo Fisher Proteome Discoverer 1.3 (Thermo Fisher Scientific) and the exported MGF files were searched by Mascot 2.3.0 search algorithm (Matrix Science, Boston, MA) against the Uniprot_human database (the time/ date of fasta file was Wed Mar 03 23:26:45 2010 and the number of sequences for taxonomy was 20,266 (Homo sapiens)) and an automatic decoy database search was performed. The parameters in Mascot were set for peptide searching, including trypsin as the digestion enzyme, cysteine carbamidomethylation as a fixed modification. iTRAQ eight-plex on the N-terminal residue, iTRAQ eight-plex on tyrosine (Y), iTRAQ eight-plex on lysine (K), Gin-Pyro-Glu (N-term Q), and oxidation on methionine (M) as variable modification. The precursor mass tolerance was set to 15 ppm for precursor ions and 20 mmu for fragment ions. Also, several parameters in Mascot were set for peptide analysis, including the number of distinct peptides assigned for each protein given as “unique” and “peptides”, the coverage of each protein assigned given as “coverage” (supplemental Table S1). The quantification measurement for each peptide and protein was illustrated as the ratio of diseased sample to normal control one, both in the cortex and cerebellum, showing as “sCJD/Nor(Cortex), FFI/Nor(Cortex), G114V/Nor(Cortex), sCJD/Nor(Cerebellum), FFI/Nor(Cerebellum), and G114V/Nor(cerebellum).”

Prerequisites for Quantifying the Proteins Labeled with iTRAQ—Based on the published data (15) and standard operating procedures (SOP) for iTRAQ-based proteomics in Beijing Institute of Genomics, Chinese Academy of Science, the prerequisites to acquire the significant changed proteins between the brains of human prion diseases and normal control were set up as following. First, a qualified protein for quantitative analysis should have at least one unique peptide labeled with iTRAQ. Second, false discovery rate (FDR) <1% was adopted for all the peptides. Third, the median of unique peptides was used as analysis method for protein ratio type, correction of isotope impurities and normalization of intensity median was considered for judging the differential proteome. The proteins whose p value <0.05 were considered the believed proteins. Finally, the proteins with 1.2-
fold changes (>1.20 increased or <0.83 decreased) relative to the normal control were considered as the differentially expressed ones based on the published reference (16, 17) and the fold changes in protein abundance were defined as the median ratio of all significantly matched spectra with tag signals.

**Ingenuity GO and Pathway Analysis**—Functional analysis of the data set was done using the Ingenuity GO (Gene Ontology) and Pathway Knowledge Base (Ingenuity Systems, Redwood City, CA, www.ingenuity.com). The functional analysis identified biological functions and/or diseases that were most significant to the data set. The analysis was done against the Ingenuity Knowledge Base. Fisher’s exact test was used to calculate a p value determining the probability that each biological function and/or disease assigned to that data set is because of chance alone. Canonical pathway analysis identified the pathways from the Ingenuity Pathway Knowledge Base that were most significant to the data set. The significance of the association between the data set and the canonical pathways was measured (1) by the ratio of the number of proteins from the data set that map to the canonical pathway divided by the total number of proteins that map to the canonical pathway and (2) by Fisher’s exact test (see above). The focus genes from the two short lists were considered algorithm (supplemental Table S1). The annotated spectra for some selected proteins (20 most up- and down-regulated proteins in cortex and 20 in cerebellum) among 2287 identified ones were showed as supplemental Table S2.

Using the standards of 1.2-, 1.5-, and 2.0-fold change, the potential differentially expressing proteins in each disease were separately counted. The exact numbers of the up- and down-regulated proteins in cortex and cerebellum tissues from the groups of sCJD, FFI, and G114V gCJD were shown in Fig. 1A. The numbers of 1.2-, 1.5-, and 2.0-fold changed proteins in cortical regions were 1178, 403, and 117 in sCJD, 878, 235, and 74 in FFI, 1314, 537 and 183 in G114V gCJD, whereas those in cerebella regions were 1412, 671, and 158 in sCJD, 1356, 622, and 221 in FFI, 1503, 765, and 316 in G114V gCJD, respectively. For exploring the potential changes in proteomic profiles among the different human prion diseases maximally, we used the proteins that were 1.2-fold increased or decreased as the differential expressing proteins in further analyses.

As shown in Fig. 1A and Table II, the numbers of the changed proteins (< or > 1.2-fold change) in the cerebellum tissues of three prion diseases were significantly higher (p = 0.039) than that of the individual cortex regions. More numbers of the changed proteins were identified in the brains of G114V gCJD and sCJD regardless of cortex or cerebellum, whereas FFI contained remarkably less changed proteins especially in the cortex regions. The portions of the up- and down-regulated proteins between two tested brain regions or among three prion diseases were almost the same.

Of those 2287 identified brain proteins, 161 (7.0%) and 151 (6.6%) were commonly up-regulated and down-regulated significantly in cortex regions, whereas 348 (15.2%) and 379 (16.6%) were commonly up-regulated and down-regulated in cerebellum regions of all diseased samples, respectively (Table II). Obviously, cerebellum tissues contained significantly more numbers of commonly changed proteins than cortex tissues (p = 0.003, Fig. 1B). The top 10 commonly up- and down-regulated proteins in the cortex and cerebellum regions of three kinds of prion disease were shown in supplemental Table S2, with the highest increase of 8.275 (adenylate kinase isoenzyme 5) in the cortex and 10.162 (electrogenic sodium bicarbonate cotransporter 1) in the cerebellum, and the lowest decrease of 0.046 (cysteine desulfurase) in the cortex and 0.075 (Kinesin-like protein KIF3A) in the cerebellum.

**Hierarchical Clustering Analysis of the Identified Brain Proteins from Different Human Prion Diseases**—To explore the relationship of the changed proteins among the three prion diseases and between the two tested brain regions, the hierarchical clustering analysis was performed in the context of all 2287 identified proteins after being normalized with the value of each protein in the group of normal controls. Two major clusters were formed (Fig. 2), revealing a region-dependent manner that the profiles of the identified proteins of three human prion diseases clustered about each other based on...
the tested brain regions. In addition, the profiles of FFI, either in cortex or cerebellum, appeared to be closer to those of sCJD than those of G114V gCJD.

Analysis of the Alternative Patterns of the Identified Brain Proteins from Different Human Prion Diseases—To obtain the overviews of the brain protein alterations in various subtypes of human prion diseases, the changing values of individual 2287 identified proteins in every disease were displayed logarithmically after being normalized with the data of normal controls. As shown in supplemental Fig. S2A, in the assays of cortex regions, G114V gCJD and sCJD appeared to have more dots in the areas of higher or lower log values than FFI, whereas in the pictures of cerebellum, the dot distributions of three prion diseases were quite similar (supplemental Fig. S2B). Furthermore, the numbers of the changed proteins were counted and grouped based on their changing folds, including
the up-regulation of [gt]2.4-fold, 1.8–2.4-fold, 1.2–1.8-fold, the down-regulation of 0.8–0.6-fold, 0.6–0.4-fold and <0.4-fold. The percentage of the changed proteins in each group was calculated in the context of whole changed proteins. As illustrated in Fig. 3, majorities of the changed proteins in cortex and cerebellum of three prion diseases were located in the mildly changed groups (1.2–1.8 fold up-regulation and 0.8–0.6 fold down-regulation). Compared with sCJD and G114V gCJD, FFI had lower percentages in the severely [gt]2.4-fold increased and <0.4-fold decreased) and moderately (1.8–2.4-fold increased and 0.6–0.4-fold decreased) changed groups in cortex, while they had lower percentages only in the severely changed groups in cerebellum. The portions of the proteins in severely and moderately changed groups of the cerebellum were higher than that of the cortex in all tested prion diseases. In addition, the ratios of down-regulated proteins in the severely and moderately changed groups were higher than that of up-regulated ones (Fig. 3).

**Involvement of Significant Pathways in Human Prion Diseases**—Considering the possible involved biological pathway of the differentially expressed proteins, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was conducted using the software of KOBAS2.0. In the region of the cortex, a total of 183 different pathways were identified in the group of sCJD and 14 possible affected biological pathways were addressed with a significant difference \( p < 0.05 \). Meanwhile, a total of 200 pathways were identified in FFI and seven with a significant difference \( p < 0.05 \), and a total of 181 pathways were identified in G114V gCJD and 13 with a significant difference \( p < 0.05 \) (Table III). Comparison of the affected pathways in cortex and cerebellum illustrated that Parkinson’s disease, Alzheimer’s disease, oxidative phosphorylation, and drug metabolism-cytochrome P450 were the commonly affected pathways, which were identified from at least two different diseases (in bold type, Table III). In the region of the cerebellum, 197 pathways were identified in sCJD and five with a significant difference \( p < 0.05 \). A total of 199 pathways were identified in FFI and five with a significant difference \( p < 0.05 \). Meanwhile, a total of 207 pathways were confirmed in G114V gCJD and 10 with a significant difference \( p < 0.05 \) (Table III). Comparison of the affected pathways in cortex and cerebellum illustrated that Parkinson’s disease, Alzheimer’s disease, oxidative phosphorylation, and drug metabolism-cytochrome P450 were the commonly affected ones. Furthermore, the involved pathways in each group were analyzed based on the proteins with more than 1.5- and 2.0-fold changed com-
pared with that in normal control. The affected pathways with a significant difference (p < 0.05) were summarized in the supplemental Tables S3 and S4. Metabolism of xenobiotics by cytochrome P450, Drug metabolism-cytochrome P450, PPAR signaling pathway, Fatty acid metabolism, Fatty acid elongation in mitochondria, and SNARE interactions in vesicular transport were commonly observed pathways in the assays based on the proteins with 1.2-, 1.5-, or 2.0-fold change (Table III).

**DISCUSSION**

The proteomics approach has been already applied to the investigation of proteome alternations in human neurodegenerative disease such as AD, PD, and CJD (18, 19, 20), mostly aiming to screen for potential biomarkers. In the present study we have applied isobaric peptide tags (iTRAQ) and multidimensional LC-MS/MS to identify proteins that are differentially expressed in the brain tissues of human prion diseases compared with normal control. Eight-plexes of samples including four samples of the cortex and four of the cerebellum.

![Fig. 3](image)

**Fig. 3.** The percentages of whole changed proteins in cortex and cerebellum regions of sCJD, FFI, and G114V sCJD based on their changing folds. The changed proteins are grouped as up-regulation (>2.4-fold, 1.8–2.4-fold, and 1.2–1.8-fold) and down-regulation (0.8–0.6-fold, 0.6–0.4-fold, and <0.4-fold) after normalized with those of normal control. The percentage of the changed proteins in each group was showed on the bottom.

**Involvement of Significant Functional Categories in Human Prion Diseases—**Based on the differentially regulated proteins in various prion diseases, GO analysis tool was performed in order to screen the affected biological functions, including biological process, molecular function, and cellular component. Each affected function was given a score automatically by software, which represented the severity of the affected biological function. The affected biological functions (with scores) in the two brain regions of three prion diseases were obtained. In line with the results of the changed proteins, the scores in cerebellum tissues of three prion diseases were slightly higher than that of the cortex tissues, and relatively lower scores were observed in the brain tissues of FFI, especially in the cortex regions. Table IV summarized the top five affected biological functions. In the context of three major functional categories and of two brain regions, the top five affected biological functions were exactly the same among sCJD, FFI, and G114V gCJD, only varying in the rank and in the score. In the ontology of biological process the top five affected biological functions were cellular process, metabolic process, response to stimulus, cellular metabolic process, and macromolecule metabolic process. In the ontology of molecular function, the top five affected biological functions were binding, protein binding, ion binding, catalytic activity, and adenyl nucleotide binding or cation binding. In addition, in the ontology of cellular component, the top five affected biological functions were cell part, cell, membrane-bounded organelle, intracellular, and organelle.
### TABLE III
KEGG Pathway analyses of the identified proteins in the brain tissues of human prion diseases. Pathways in bold type represent the commonly involved ones identified from at least two different diseases.

| Region          | Group          | Number | Pathway                                               | p value | UniProt accession                                                                 |
|-----------------|----------------|--------|-------------------------------------------------------|---------|------------------------------------------------------------------------------------|
| Cortex          | sCJD vs. Ctrl  | 1      | Viral myocarditis                                      | 0.0004  | C9JK3, P06241, B4DLJ8, P05324, P01860, P01876, P01861, P35579,  |
|                 |                | 2      | Intestinal immune network for IgA production          | 0.0012  | B4DLJ8, P01860, P01876, P01861, P35579,  |
|                 |                | 3      | Asthma                                                | 0.0013  | P01860, P01876, P01861, P35579,  |
|                 |                | 4      | Staphylococcus aureus                                 | 0.0017  | P01860, P01876, P01861, P35579,  |
|                 |                | 5      | Primary immunodeficiency                               | 0.0018  | P01860, P01876, P01861, P35579,  |
|                 |                | 6      | Autoimmune thyroid                                    | 0.0019  | P01860, P01876, P01861, P35579,  |
|                 |                | 7      | Chioroalkane and chloroalkene degradation             | 0.0020  | P01860, P01876, P01861, P35579,  |
|                 |                | 8      | Fc gamma R-mediated phagocytosis                      | 0.0021  | P01860, P01876, P01861, P35579,  |
|                 |                | 9      | African trypanosomiasis                               | 0.0022  | P01860, P01876, P01861, P35579,  |
|                 |                | 10     | Parkinson's disease                                   | 0.0023  | P01860, P01876, P01861, P35579,  |
|                 |                | 11     | Leishmaniasis                                         | 0.0024  | P01860, P01876, P01861, P35579,  |
|                 |                | 12     | Alzheimer's disease                                   | 0.0025  | P01860, P01876, P01861, P35579,  |
|                 |                | 13     | Fc epsilon RI signaling pathway                      | 0.0026  | P01860, P01876, P01861, P35579,  |
|                 |                | 14     | Lysosome                                              | 0.0027  | P01860, P01876, P01861, P35579,  |
|                 | FF1 vs. Ctrl   | 1      | Viral myocarditis                                      | 0.0028  | B4DLJ8, P01860, P01876, P01861, P35579,  |
|                 |                | 2      | Amyotrophic lateral sclerosis (ALS)                  | 0.0029  | P01860, P01876, P01861, P35579,  |
|                 |                | 3      | Phosphoinositid signaling system                     | 0.0030  | P01860, P01876, P01861, P35579,  |
|                 |                | 4      | Phosphatidylinositol signaling system                | 0.0031  | P01860, P01876, P01861, P35579,  |

**Note:** The table entries are truncated for brevity. The full table can be found in the original source.
| Region Group          | Number | Pathway                                      | p value | Count | UniProt accession |
|----------------------|--------|----------------------------------------------|---------|-------|-------------------|
| **Protein export**   | 5      | 5                                             | 0.0224  | 5     | F8W776, P49458, P11021, P37106, P61619 |
| **Hematopoietic cell lineage** | 6      | 6                                             | 0.0261  | 7     | E9PNW4, P01860, D6RFL4, P01857, A8NN4, P01876, P01877 |
| **p53 signaling pathway** | 7      | G114V vs. Ctrl                                | 0.0432  | 3     | C9JFR7, P55957, E9PJ7 |
| **ECM-receptor interaction** | 1      | 1                                             | 0.0023  | 15    | P55268, Q7L0J3, Q7L112, Q08722, Q82752, H2N331, E7EWZ6, B4DHDA, E9PFQ6, P08123, P05556, Q14118, H0YDI3, P12109, E9P0C4 |
| **Oxidative phosphorylation** | 2      | 2                                             | 0.0033  | 66    | H3BNX8, Q3NX14, 075251, E9PRJ5, C9JSN6, P61421, P19404, Q9P0J0, Q86Y39, Q8U12, Q8N8Y2, Q16718, E9PICO, A14561, P21281, P47985, Q16795, P151970, O75306, P07919, P38606, P14406, D6RJ06, G3V015, P13073, 075438, Q96II6, P28331, E9PPW7, P21283, 075489, F5H568, Q95299, G3V2S6, P56556, Q18684, P36543, P36542, 075964, P22695, P25705, P21912, C9J8H9, Q00483, P15954, P04043, C9J9J2, P31930, P09268, Q9UDW1, E7EWP0, P06576, P10606, O43920, P30049, P14854, P24539, P24311, O95168, O95182, P48047, D6R97H, Q15904, P03891, Q9H008 |
| **Metabolism of xenobiotics by cytochrome P450** | 3      | 3                                             | 0.0061  | 13    | O14880, G3V389, P78417, P11766, P28161, Q9Y2Q3, P09211, P21266, P30711, P07099, F5H7F6, P09488, P46439 |
| **Focal adhesion**   | 4      | 4                                             | 0.0073  | 38    | H7C144, P55268, B2RCS5, P05771, O43707, Q13153, D7R525, P12814, Q92752, 07ET75, P46109, B4DGJ4, F8VYEB, P28482, O75369, P62140, H2N331, E7EWZ6, B4DHDA, E9PFQ6, P08123, P06241, Q8Y490, P05556, E9P597, P19206, Q5HY54, P00633, Q14315, F8V8B4, P17655, C9J9J3, P17252, B7Z101, P12109, Q6P2N0, E9P0C4 |
| **Toxoplasmosis**    | 5      | 5                                             | 0.0091  | 15    | P63096, P55268, P09471, C9JFR7, P17066, D7R525, P11142, P04999, P28482, P30405, C9K0I3, P05556, P56452, P08754, B4DLJ8 |
| **Drug metabolism - cytochrome P450** | 6      | 6                                             | 0.0212  | 13    | O14880, G3V389, P78417, P11766, P28161, Q9Y2Q3, P09211, P21266, P30711, F5H7F6, P27338, P09488, P46439 |
| **Arrhythmicogenic right ventricular cardiomyopathy (ARVC)** | 7      | 7                                             | 0.0295  | 19    | H7C144, E7EN11, B2RCS5, O43707, C9JE82, P52489, P12814, F8VUV8, E5RG03, B4DGJ4, H2N331, Q6UYC3, E7EWZ6, B4DHDA, QSSW23, P05556, Q14118, P17302, P46439 |
| **Glutathione metabolism** | 8      | 8                                             | 0.0305  | 21    | P48735, Q9U14, O14880, G3V389, P78417, Q9S81, B4DE40, P19623, B4DGJ8, Q75874, P28161, Q9Y2Q3, P11413, P09211, P12266, P28888, P30711, F5H7F6, P36269, P09488, P46439 |
| **Collecting duct acid secretion** | 9      | 9                                             | 0.0389  | 9     | P61421, Q8N8Y2, P21281, P38606, P21283, F5H568, G3V2S6, Q16864, P36543 |
| **Protein export**   | 10     | 10                                            | 0.0409  | 6     | F8W776, P11021, P37108, P49458, P61619, D6RY6 |
| **Lysosome**         | 11      | 11                                            | 0.0416  | 22    | Q00610, P61421, P04996, Q8U12, Q8N8Y2, P10253, O14167, F5H569, P0947, Q15904, G3V2S6, B4DG77, Q14108, F5H241, P07858, E9PMG2, P11279, P07339, O14773, P07602, E7EMM4, B4E2S7 |
| Region         | Group                  | Number | Pathway                                      | p value  | Count | UniProt accession                                                                 |
|---------------|------------------------|--------|----------------------------------------------|----------|-------|-----------------------------------------------------------------------------------|
| 12            | Alzheimer's disease    | 0.044  | P48454, H3BNX8, Q9NX14, P16298, E7EPV7, O75251, Q9NQ66, E9PRJ5, C9JSN6, P19404, Q9POJ0, Q66Y39, Q08209, Q16718, P62158, E9PICO, O14561, P47985, Q16795, P51970, O75306, P07919, P14406, D6RJD6, G3V015, P13073, F6U1T9, O75438, Q6916, P28331, O75489, O65299, C9JFR7, P56566, P36542, P22965, P25705, P21912, O00483, P15954, P00403, C9JKQ2, P55957, P31930, P00969, P09846, Q9UDW1, E7EW0, P06576, P10606, O34920, P30049, P14854, P24539, B72Z0Y, P16615, P14854, P24311, O95168, O95182, P48047, D6R9H7, Q93084, P28482, P17665, H0YEH5 |
| 13            | Parkinson's disease    | 0.049  | H3BNX8, Q9NX14, E7EPV7, O75251, Q43464, E9PRJ5, C9JSN6, P19404, Q9POJ0, Q66Y39, Q16718, E9PICO, O14561, Q99719, P47985, Q16795, P51970, O75306, P07919, P14406, D6RJD6, G3V015, P13073, O75438, Q6916, P09936, P28331, P12235, E9PPW7, O75489, O65299, P12235, C9JFR7, P56566, P36542, P22695, P25705, P21912, O00483, P15954, P00403, C9JKQ2, P31930, P09869, P09846, Q9UDW1, E7EW0, P06576, P10606, O34920, P30049, P14854, P24539, P24311, O95168, O95182, P48047, D6R9H7, P03891, P22314 |
| Cerebellum    | sCJD vs. Ctrl          | 1      | P02656, P02652, P02647, P07108, F5H0M0, H0Y9U7, Q9BX66, B72110, E166W5, O937DE9, G3V189, P00413, P50416, B4DJE7, O15540, A8MW49 |
| 2             | Nitrogen metabolism    |        | P22748, O9425, P00367, P00918, E5RJ8, P15104, P35219, P31327 |
| 3             | Malaria                | 0.0295 | P04921, E9JK1, P05362, P08871, P69905, Q07954, P02042 |
| 4             | Complement and         | 0.0322 | P10726, E9PNW4, A6H8M8, P01024, P00488, P02679, H7C5H1, P02671, P02675, P10009 |
| 5             | coagulation cascades   |        | F8W031, F8WE3, P21399, F5GXC8, E9PB14, P40925, P31040, E9PICO, P40926, P33396, E9PF84, P21912, O43837, P48735, P50213, P10515, F5H801, P07954, P08559, P11177, Q99798, B4D4V2 |
| FFI vs. Ctrl  | Huntington's disease   | 0.0017 | B3KUK2, P20674, P00441, P13073, Q00059, E5RJ8, P09497, P00395, O08752, P18859, O00483, P14927, Q9NQ66, P0176, O75438, P09496, D6R9H7, C9JSN6, P56181, P63010, Q5W145, E9PICO, P45880, O75947, P08574, P30049, O14561, O6516, P24311, O94973, A8MV48, P25705, P50148, P48047, Q9UO9, P31040, O43920, E7EW0, H3BNX8, P21912, Q9UDW1, Q96610, P12235, P14406, P06576, P24539, Q9Y277, O75306, P0846, P15670, P05141, P47985, P36542, P31930, P26885, P16718, P00403, O75489, P19404, D6RJD6, E9PPW7, Q16795, P28331, G3V015, Q969M3, P90040, O16029, Q96589, O95299, O75351, G5E9P1, P56566, O95168 |
| Region                        | Group | Number Pathway | p value | Count | UniProt accession |
|------------------------------|-------|----------------|---------|-------|-------------------|
| 2                            |       | Parkinson's disease | 0.0040  | 64    |                   |
| 3                            |       | Oxidative phosphorylation | 0.0049  | 65    |                   |
| 4                            |       | Alzheimer's disease | 0.0212  | 67    |                   |
| 5                            |       | beta-Alanine metabolism | 0.0483  | 13    |                   |
| 6                            |       | Ribosome | 0.0010  | 46    |                   |
| 7                            |       | Peroxisome | 0.0014  | 22    |                   |
| 8                            |       | Metabolism of xenobiotics | 0.0132  | 13    |                   |

Proteomics Analyses of Human Prion Disease

Molecular & Cellular Proteomics 14.4
| Region | Group | Number | Pathway                                | p value | Count | UniProt accession                                                                 |
|--------|-------|--------|----------------------------------------|---------|-------|-----------------------------------------------------------------------------------|
| 4      |       | 4      | Fatty acid metabolism<sup>a</sup>       | 0.0180  | 21    | P11766, F5GWH2, P42765, H0Y9U7, G3V1S9, Q92947, P49748, F5H0M0, P49189, P9419, P24752, C9JDE9, P30084, E9PE82, P40939, B4E2W0, P50416, B4DJE7, P05091, Q16836, P30837 |
| 5      |       | 5      | Adipocytokine signaling pathway         | 0.02371 | 8     | J3KPZ9, D7R525, F5GWH2, H0Y9U7, Q06124, G3V1S9, P42345, P50416                      |
| 6      |       | 6      | Butanoate metabolism<sup>a</sup>       | 0.02969 | 14    | Q9259, P80404, P08595, P55809, P11177, Q02338, P24752, Q9BUT1, C9J8GQ5, P30084, B1AK13, E9PE82, P40939, Q16836 |
| 7      |       | 7      | Cell adhesion molecules (CAMs)          | 0.0364  | 26    | E9PD27, H0YGA7, Q8N126, A6NIW1, B4DFI2, Q9HDB5, A8MWK3, F5G9Y0, P13591, P30204, Q12860, P05362, Q7Z3B1, Q9BX67, Q9UHY6, P78367, H7BY57, Q02246, P05566, E9PF17, F8W8X7, B7ZKN0, E9PPA4, H3BM42, B4DLJ8, B4DHD4 |
| 8      |       | 8      | Fatty acid elongation in mitochondria<sup>a</sup> | 0.0379  | 7     | P42765, E9PMG2, P30084, Q9BV79, P40939, B4E2W0, Q16836 |
| 9      |       | 9      | Drug metabolism - cytochrome P450<sup>a</sup> | 0.0422  | 13    | F5H7F6, P11766, P78417, G3V3B9, Q9Y2Q3, P28161, P21266, Q6ICJ4, P09211, P30711, P27338, P46439, P09488 |
| 10     |       | 10     | SNARE interactions in vesicular transport<sup>a</sup> | 0.0440  | 10    | P60880, P63027, Q2VPS2, Q95183, F5H787, O15400, Q16623, H0YJL5, Q75396, C9JF35 |

<sup>a</sup>The pathway also appeared in the 1.5-fold changed proteins with \( p < 0.05 \).

<sup>b</sup>The pathway also appeared in the twofold changed proteins with \( p < 0.05 \).
| Region     | Ontology                          | sCJD vs. Ctrl | FFI vs. Ctrl | G114V vs. Ctrl |
|------------|-----------------------------------|--------------|--------------|---------------|
| Cortex     | **Cellular component**            |              |              |               |
|            | 1 Cell part (678.86)              | Cell part (543.65) | Cell part (872.69) |               |
|            | 2 Cell (407.31)                   | Cell (326.19) | Cell (523.62) |               |
|            | 3 Membrane-bounded organelle (364.98) | Membrane-bounded organelle (275.57) | Intracellular part (421.13) | Membrane-bounded organelle (419.78) |
|            | 4 Intracellular part (314.20)     | Intracellular part (250.38) | Membrane-bounded organelle (419.78) |               |
|            | 5 Organelle (298.74)              | Organelle (221.51) | Organelle (345.89) |               |
| Biological process | **Cellular component**            |              |              |               |
|            | 1 Cellular process (508.23)       | Cellular process (396.16) | Cellular process (648.34) |               |
|            | 2 Metabolic process (257.79)      | Metabolic process (209.38) | Metabolic process (323.90) |               |
|            | 3 Response to stimulus (241.98)   | Response to stimulus (206.35) | Response to stimulus (307.07) |               |
|            | 4 Macromolecule metabolic process (189.32) | Macromolecule metabolic process (137.55) | Cellular metabolic process (230.22) | Macromolecule metabolic process (229.83) |
|            | 5 Cellular metabolic process (177.85) | Cellular metabolic process (136.51) | Macromolecule metabolic process (229.83) |               |
| Molecular function | **Cellular component**            |              |              |               |
|            | 1 Binding (555.99)                | Binding (436.47) | Binding (733.36) |               |
|            | 2 Protein binding (274.18)        | Protein binding (212.27) | Protein binding (334.31) |               |
|            | 3 Catalytic activity (125.60)     | Catalytic activity (96.23) | Catalytic activity (167.58) |               |
|            | 4 Ion binding (121.09)            | Ion binding (81.24) | Ion binding (164.80) |               |
|            | 5 Adenyl nucleotide binding (118.00) | Adenyl nucleotide binding (90.00) | Adenyl nucleotide binding (145.60) |               |
| Cerebellum | **Cellular component**            |              |              |               |
|            | 1 Cell part (924.34)              | Cell part (882.29) | Cell part (991.78) |               |
|            | 2 Cell (554.60)                   | Cell (517.38) | Cell (585.07) |               |
|            | 3 Membrane-bounded organelle (458.33) | Membrane-bounded organelle (446.41) | Membrane-bounded organelle (499.79) |               |
|            | 4 Intracellular part (441.17)     | Intracellular part (405.30) | Intracellular part (467.71) |               |
|            | 5 Organelle (377.52)              | Organelle (362.08) | Organelle (406.68) |               |
| Biological process | **Cellular component**            |              |              |               |
|            | 1 Cellular process (663.51)       | Cellular process (619.11) | Cellular process (712.05) |               |
|            | 2 Metabolic process (362.57)      | Metabolic process (341.51) | Metabolic process (387.81) |               |
|            | 3 Response to stimulus (335.94)   | Response to stimulus (326.70) | Response to stimulus (358.75) |               |
|            | 4 Cellular metabolic process (253.07) | Macromolecule metabolic process (212.11) | Cellular metabolic process (261.92) | Macromolecule metabolic process (259.84) |
|            | 5 Macromolecule metabolic process (231.36) | Cellular metabolic process (243.87) | Macromolecule metabolic process (259.84) |               |
| Molecular function | **Cellular component**            |              |              |               |
|            | 1 Binding (780.06)                | Binding (745.15) | Binding (828.97) |               |
|            | 2 Protein binding (359.02)        | Protein binding (330.03) | Protein binding (381.59) |               |
|            | 3 Ion binding (173.86)            | Catalytic activity (173.74) | Ion binding (187.67) |               |
|            | 4 Catalytic activity (173.90)     | Ion binding (168.99) | Catalytic activity (187.12) |               |
|            | 5 Adenyl nucleotide binding (154.20) | Cation binding (138.32) | Cation binding (156.12) |               |
are subjected to the proteomic assay at the same time in one approach. In total, 2287 potential proteins have been detected in human brain specimens with 95% confidence interval based on such approach.

In general, 312 and 727 commonly changed proteins in the regions of cortex and cerebellum among sCJD, FFI, and G114V gCJD have been identified, which occupy 13.6% and 31.8% of total identified proteins. Of the top 10 up-regulated proteins in the cortex and cerebellum, almost one third proteins relate with the functions of metabolic processes and one third relate with protein transport. The others proteins in the group of top 10 up-regulated proteins included heme-binding protein2 (20) and integral membrane protein 2B (21), which are associated with Alzheimer’s disease (AD). In the group of up-regulated proteins in the cerebellum, AFG3-like protein 2(22) and Ataxin-10 (23) have been described to be related with development of nervous system symptoms such as ataxia and Acyl-coenayme A, Electrogenic sodium bicarbonate cotransporter-1(24) are related with pathogenesis of nervous system disease. Coronin-2B (also known as actin binding protein) plays a role in the reorganization of neuronal actin structure (25). Of the top 10 down-regulated proteins in cortex and cerebellum, almost two third proteins relate with the function of metabolic process. Four other proteins are associated with transport, such as Formin-2 in the cortex region, which is an actin-binding protein involving in actin cytoskeleton assembly and reorganization (26), the vacular protein sorting-associated protein 51 homolog in cerebellum region, which acts as component of the GARP complex involved in retrograde transport from early and late endosomes to the trans-Golgi network (TGN). Obviously, the functions of the metabolic process and protein transport in the brain tissues are most severely affected at the final stage of human prion diseases.

Using GO analysis, we have confirmed that the top five of the affected biological functions, including cellular component, biological process and molecular function, are completely identical in the tested samples of parietal lobe and cerebellum from sCJD, FFI, and G114V gCJD cases. Using KEGG pathway analysis, we have identified a series of significantly changed pathways. Some changed pathways, such as PD, AD, oxidative phosphorylation, lysosome, viral myocarditis, and protein export, are commonly observed among these three prion diseases, either in the cortex or cerebellum regions. It highlights that although the etiological agents and the pathogenesis may differ from each other, the global proteomic profiles in brain tissues of the three human TSEs at terminal stage possess great similarity. Interestingly, the pathways of PD, AD, and oxidative phosphorylation are also the most significantly changed ones in the assays of the global gene expression patterns in the thalamus and parietal lobe of the three Chinese FFI cases (6) and in the parietal lobe of a Chinese G114V gCJD patient (7). Such phenomena are also detected when we comparatively analyze the global transcriptional profiles in the cortex regions of Caucasian sCJD patients (27) and Chinese FFI cases (28). These data strongly indicate a good agreement of proteomics patterns and transcriptomics patterns in identifying the affected pathways in the pathogenesis of human TSEs. Moreover, our data here also propose some other affected pathways related with neurodegenerative diseases like Amyotrophic lateral sclerosis (ALS) and Huntington’s disease either in the tested cortex or cerebellum. It verifies again the similarity in the contexts of the global transcriptional and translational profiles in the brains of human neurodegenerative diseases at final stage.

Our proteomic data also reveal disease-associated characteristics in the differentially expressed proteins. Compared with sCJD and G114V gCJD, FFI contains less numbers of differentially expressed proteins and lower percentages differentially expressed proteins with severe (gt)2.4-fold increased and <0.4-fold decreased) and moderate (1.8–2.4-fold increased and 0.6–0.4-fold decreased) changes, especially in the cortex regions. This profile coincides well with the neuropathology of FFI that has severe abnormalities in thalamus but usually has obviously mild changes in cortex regions (29). The numbers of differentially expressed proteins in sCJD and G114V gCJD are quite comparable and the commonly changed pathways are more frequently identified between sCJD and G114V gCJD. Further review of the neuropathological features of the patient with G114V gCJD highlights a sCJD-like pattern, showing obvious spongiform degeneration accompanied by large amounts of PrPSc deposits (13), which may partially explain the closer similarity in the brain proteomic patterns between sCJD and G114V gCJD.

We have noticed that regardless of sCJD, FFI, or G114V gCJD, the regions of the cerebellum contain significantly more numbers of both differentially expressed proteins and the commonly changed proteins, meanwhile, the ratios of severely and moderately changed proteins in cerebellum are markedly higher than in cortex. In addition, despite the top five affected biological functions being exactly the same in the groups of cortex and cerebellum, much higher scores are seen in cerebellum. It seems that the alterations of global proteins in cerebellum of human TSEs are severe. The exact reason for this diversity between cortex and cerebellum remains unknown, though review of the clinical data of all tested patients proposes the presence of cerebellum-associated manifestations, such as ataxia, which may reflect the damage of cerebellum (11,13). The bias of individual difference might be at least partially excluded, as the normal control used in this study derives from three health individuals. Further study with more cases will help us to address this phenomenon.

The increase of PrP protein is not found either in the cortex or cerebellum region of human TSEs. On the contrary, the signals of PrP protein in all tested samples are even lower than that of control. Large amounts of PrPSc have been observed in both cortex and cerebellum regions of those enrolled sCJD and G114V gCJD (13). PrPSc signals are also
detectable in the brains of three FFI cases, with remarkably lower PK resistance (29). As the obvious structural changes from PrPSc to PrPSc with PK resistance, which offers the latter the resistance to proteolysis, we speculate that the strong PK-resistance of PrPSc in the brain tissues of human TSEs will dramatically influence the processes for protein purification and trypsin digestion during proteomics assays. In line with the presence of obvious gliosis and neuron loss in cortex and cerebellums of sCJD and G114V gCJD (4), our proteomic data have also illustrated up-regulated GFAP that is the biomarker for astrocytes and down-regulated NSE and MAP-2 that are the biomarkers for neurons in the tested samples of sCJD and G114V gCJD (4).

The rapid development of proteomics technologies and high sensitivity of the iTRAQ combined with multidimensional LC and MS detection allow us not only to identify but also to quantify the protein change in the tested samples. Controlled with the technology of iTRAQ, more less-changed proteins could be identified with traditional 2D-gel images and MS. With such methods, we have explored the global differential expression patterns of brain proteins and proposed the significantly affected pathways in several subtypes of human TSEs. The discovery of a high number of changes in proteomics of human prion diseases may provide useful clues in the search for potential biomarkers for diagnosis of different types of human prion disease.

* This work was supported by Chinese National Natural Science Foundation Grants (81301429, China Mega-Project for Infectious Disease (2011ZX10004-101, 2012ZX10004-215), and SKLID Development Grant (2012SKLID012).

This article contains supplemental Fig. S1 and Tables S1 to S4. To whom correspondence should be addressed: Prion Department, China CDC, Changbai Rd 155, Chaoyang District, Beijing 102206, China. Tel.: 86-10-58900815; E-mail: dongsx238@sina.com.

REFERENCES

1. Liberski, P. P. (2012) Historical overview of prion diseases: a view from afar. *Folia Neuropathol. 50*, 1–12
2. Colby, D. W., and Prusiner, S. B. (2011) Prions. *Cold Spring Harb. Perspect. Biol. 3a*, 006833
3. Shi, Q., Jing, Y. Y., Wang, S. B., Chen, C., Sun, H., Xu, Y., Gao, C., Zhang, J., Tian, C., Guo, Y., Ren, K., and Dong, X. P. (2013) PrP octarepeats region determined the interaction with caveolin-1 and phosphorylation of caveolin-1 and Fyn. *Med. Microbiol. Immunol. 202*, 215–227
4. Guo, Y., Gong, H. S., Zhang, J., Xie, W. L., Tian, C., Chen, C., Shi, Q., Wang, S. B., Xu, Y., Zhang, B. Y., and Dong, X. P. (2012) Remarkable reduction of MAP2 in the brains of scrapie-infected rodents and human prion disease possibly correlated with the increase of calpain. *PloS One 7*, e30163
5. Gong, H. S., Guo, Y., Tian, C., Xie, W. L., Shi, Q., Zhang, J., Xu, Y., Wang, S. B., Zhang, B. Y., Chen, C., Liu, Y., and Dong, X. P. (2012) Reduction of protein kinase MARK4 in the brains of experimental scrapie rodents and human prion disease correlates with deposits of PrPSc. *Int. J. Mol. Med. 30*, 569–578
6. Tian, C., Liu, D., Sun, Q. L., Chen, C., Xu, Y., Wang, S. B., Zhang, B. Y., Chen, C., Liu, Y., and Dong, X. P. (2013) Comparative analysis of gene expression profiles between cortex and thalamus in Chinese fatal familial insomnia patients. *Mol. Neurobiol. 48*, 36–48
7. Tian, C., Liu, D., Chen, C., Xu, Y., Gong, H.S., Chen, C., Shi, Q., Zhang, B. Y., Han, J., and Dong, X. P. (2013) Global transcriptional profiling of the postmortem brain of a patient with G114V genetic Creutzfeldt-Jakob disease. *Int. J. Mol. Med. 31*, 676–688
8. Otto, A., Becher, D., and Schmidt, F. (2014) Quantitative Proteomics in the field of Microbiology. *Proteomics 14*, 547–565
9. Martinez-Esteso, M. J., Casado-Vela, J., Selles-Marchart, S., Pedreno, M. A., and Bru-Martinez, R. (2014) Differential plant proteome analysis by isobaric tags for relative and absolute quantitation (iTRAQ). *Methods Mol. Biol. 1072*, 155–169
10. Evans, C., Noirel, J., Ow, S. Y., Salim, M., Pereira-Medrano, A. G., Couto, N., Pandhal, J., Smith, D., Pham, T. K., Karunakanaran, E., Zou, X., Biggs, C. A., and Wright, P. C. (2012) An insight into iTRAQ: where do we stand now? *Anal. Bioanal. Chem. 401*, 1011–1027
11. Shi, X. H., Han, J., Zhang, J., Shi, Q., Chen, J. M., Xia, S. L., Xie, Z. Q., Shen, X. J., Shan, B., Lei, Y. J., Shi, S., Zhou, W., Zhang, B. Y., Gao, C., Liu, Y. H., Song, J., Guo, Y. J., Wang, D. X., Xu, B. L., and Dong, X. P. (2010) Comprehensive histopathological, and genetic studies in a family with fatal familial insomnia. *Infect. Genet. Evol. 10*, 292–297
12. Shi, Q., Chen, C., Gao, C., Tian, C., Zhou, W., Zhang, B., Han, J., and Dong, X. P. (2012) Clinical and familial characteristics of ten chinese patients with fatal family amyloidosis. *Biomed. Environ. Sci. 25*, 471–475
13. Shi, Q., Zhang, B. Y., Gao, C., Han, J., Wang, G. R., Chen, T., and Dong, X. P. (2012) The diversities of PrPSc distributions and pathologic changes in various brain regions from a Chinese patient with G114V genetic CJD. *Neuropathology 32*, 51–59
14. Zhang, J., Chen, L., Zhang, B. Y., Han, J., Xiao, X. L., Tian, H. Y., Li, B. L., Gao, C., Gao, J. M., Zhou, X. B., Ma, G. P., Liu, Y., Xu, C. M., and Dong, X. P. (2004) Comparison study on clinical and neuropathological characteristics of hamsters inoculated with scrapie strain 263K in different challenging pathways. *Biomed. Environ. Sci. 17*, 65–78
15. Chen, J., Ren, B., Wang, Q., Tong, W., Guo, J., Bai, X., Zhao, J., Sun, Y., Tang, Q., Lin, Z., Lin, L., and Liu, S. (2013) Quantitative proteomics reveals the temperature-dependent proteins encoded by a series of cluster genes in thermoanabacter tengcongensis. *Mol. Cell. Proteomics 12*, 2266–2277
16. Ren, Y., Hao, P., Dutta, B., Cheow, E. S., Sim, K. H., Gan, C. S., Lim, S. K., and Sze, S. K. (2013) Hypoxia modulates A431 cellular pathways associated to tumor radioresistance and enhanced migration revealed by comprehensive proteomic and functional studies. *Mol. Cell. Proteomics 12*, 495–498
17. Pierce, A., Unwin, R. D., Evans, C. A., Griffiths, S., Carney, L., Zhang, L., Jaworska, E., Lee, C. F., Blinc, D., Okniewski, M. J., Miller, C. J., Bitton, D. A., Spooncer, E., and Whetten, A. D. (2008) Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases. *Mol. Cell. Proteomics 7*, 853–863
18. Swonkley, A. M., Forster, S., Keeney, J. T., Tripplett, J., Zhang, Z., Sultana, R., and Butterfield, D. A. (2014) Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. *Biochim Biophys Acta 1842*, 1248–1257
19. Schmid, A. W., Fauvet, B., Moniatte, M., and Lashuel, H. A. (2013) Alpha-synuclein post-translational modifications as potential biomarkers for parkinson disease and other synucleinopathies. *Mol. Cell. Proteomics 12*, 3543–3558
20. Campisi, E., Cardone, F., Graziano, S., Galeno, R., and Pocchiari, M. (2012) Role of proteomics in understanding prion infection. *Expert Rev. Proteomics 9*, 649–666
21. Mansourian, M., Madadkar-Sobhani, A., Mahnam, K., Fasahi, A., and Saghaie, L. (2012) Characterization of adenosine receptor in its native environment: insights from molecular dynamics simulations of palmitoylated/glycosylated, membrane-integrated human A2B adenosine receptor. *J. Mol. Model 18*, 4309–4324
22. Lobbe, A. M., Kang, J. S., Hilker, R., Hackstein, H., Muller, U., and Nolte, D. (2014) A novel missense mutation in AFG3L2 associated with late onset frontoparietal ataxia type 28. *J. Mol. Neurosci. 52*, 493–496
23. Cheng, X., Gan, L., Zhao, J., Chen, M., Liu, Y., and Wang, Y. (2013) Changes in Ataxin-10 expression alter sciatric nerve crush in adult rats. *Neurochem. Res. 38*, 1013–1023
24. Oehlke, O., Speer, J. M., and Roussa, E. (2013) Variants of the electrogenic sodium bicarbonate cotransporter 1 (NBCe1) in mouse hippocampal neurons are regulated by extracellular pH changes: evidence for a Rab6a-dependent mechanism. *Int. J. Biochem. Cell Biol. 45*, 1427–1438
25. Lemieux, M. G., Janzen, D., Hwang, R., Roldan, J., Jarchum, I., and Knetch, D. A. (2014) Visualization of the actin cytoskeleton: Different F-actin-binding probes tell different stories. Cytoskeleton 71, 157–169

26. Ramabhadran, V., Hatch, A. L., and Higgs, H. N. (2013) Actin monomers activate inverted formin 2 by competing with its autoinhibitory interaction. J. Biol. Chem. 288, 26847–26855

27. Xiang, W., Windl, O., Westner, I. M., Neumann, M., Zerr, I., Lederer, R. M., and Kretzschmar, H. A. (2005) Cerebral gene expression profiles in sporadic Creutzfeldt-Jakob disease. Ann. Neurol. 58, 242–257

28. Tian, C., Liu, D., Xiang, W., Kretzschmar, H. A., Sun, Q. L., Gao, C., Xu, Y., Wang, H., Fan, X. Y., Meng, G., Li, W., and Dong, X. P. (2014) Analyses of the similarity and difference of global gene expression profiles in cortex regions of three neurodegenerative diseases: sporadic Creutzfeldt-Jakob disease (sCJD), fatal familial insomnia (FFI), and Alzheimer’s disease (AD). Mol. Neurobiol. 50, 473–481

29. Xie, W. L., Shi, Q., Xia, S. L., Zhang, B. Y., Gong, H. S., Wang, S. B., Xu, Y., Guo, Y., Tian, C., Zhang, J., Xu, B. L., Liu, Y., and Dong, X. P. (2013) Comparison of the pathologic and pathogenic features in six different regions of postmortem brains of three patients with fatal familial insomnia. Int. J. Mol. Med. 31, 81–90

30. Shi, Q., Xie, W. L., Zhang, B., Chen, L. N., Xu, Y., Wang, K., Ren, K., Zhang, X. M., Chen, C., Zhang, J., and Dong, X. P. (2013) Brain microglia were activated in sporadic CJD but almost unchanged in fatal familial insomnia and G114V genetic CJD. Virol. J. 10, 216